



## NEWS RELEASE

### DEFYRUS AND NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) SIGN NON-CLINICAL EVALUATION AGREEMENT

For Immediate Release

March 12<sup>th</sup>, 2009

---

**Toronto** - Defyrus Inc. today announced the signature of a three year Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Disease (NIAID), an institute of the U.S. National Institutes of Health (NIH). NIAID will fund the evaluation of the company's broad spectrum anti-viral drug, DEF201, through its contract testing laboratories.

Using jointly developed protocols, DEF201 will be evaluated by the Division of Microbiology and Infectious Diseases (DMID) Virology Branch in vivo models for broad spectrum antiviral activity against biodefense and emerging threat pathogens including: Venezuelan Equine Encephalitis, Punta Toro, West Nile Virus, Dengue, Yellow Fever, Pichinde, respiratory viruses (SARS) and pox viruses (Vaccinia) and avian influenza (H5N1).

“Our collaboration with NIAID provides comprehensive non-clinical evaluation of DEF201 within well characterized, established viral disease models of infection in world-class laboratories” said Jeffrey Turner, President & CEO, “such preclinical data is essential for evidence-based decisions within our antiviral drug development program”.

#### **About NIAID**

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at <http://www.niaid.nih.gov>.

#### **About NIH**

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit <http://www.nih.gov>.

#### **About Defyrus**

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and vaccines as medical countermeasures to bioterrorist threats and emerging infectious diseases. [www.defyrus.com](http://www.defyrus.com)



###

**For further information:**

Dr. Jeffrey D. Turner  
President & CEO  
Tel: (613) 674-1138  
info@defyrus.com

Mr. Dana Rath  
Chief Financial Officer  
Tel: (514) 231-3554  
info@defyrus.com